Uncategorized

You Won’t Believe What’s Coming… And I’ve Got the Tickers

We’re at a very unique point in time right now. We’re in the early stages of what I’m calling the “Roaring 2020s” – a decade that I believe will present endless and massive moneymaking opportunities for investors. I’m talking about everything from tech stocks in the U.S. and abroad to the rise of the blockchain and altcoins to the emergence of frontier countries that will grow into the next China. In today’s new episode of MoneyLine, I want to help you make the most of these opportunities. And to do that, I highlight four of the most exciting trends of the decade to come. The first is biotech, and longtime MoneyWire readers know that I’ve been bullish on this industry for years.

13 Things to Know About the GameStop-Microsoft Deal

GameStop (GME) and Microsoft (MSFT) have signed a multi-year deal that includes several upgrades and a new offering for GME stores.

5 Gen Z Stocks to Buy for Long-Term Gains

A bet on Gen Z stocks is a bet on the future, and these long-term stocks are winning over Gen Z hearts (and wallets).

If You Can Stomach It, Intel Stock Here Seems Like a Solid Discount

With so many technology-based investments soaring in 2020, Intel stock languishing in the doldrums is a huge disappointment. But for patient contrarians, this could be an incredible discount.

What Is 5G? Answer That Question and Upload Profits

Properly answering the question of what 5G is should lead to the most profit potential in both slow-growth and high-risk 5G stocks.

2 SPACs You Need to Know About – And So Many Others

It’s been a crazy few days in the world. But then again, it’s 2020. So that’s par for the course. Since my last MoneyLine podcast aired on Friday, the president was admitted to Walter Reed National Military Medical Center with COVID-19 and then released yesterday. The market is watching. Stocks initially fell on the news before rallying to kick off this week. The S&P 500 is now at its best level in a month and within striking distance of its best level EVER. I’ll go over all the details of the last few days in today’s new episode of MoneyLine. We’ll discuss if the recent buying has been driven by President Trump’s return to the White House or if it has more to do with the poll numbers swinging in favor of Joe Biden.

SPAC News: 13 Things to Know About the Clover Health Deal

Clover Health news for Tuesday includes plans to go public via a merger with SPAC Social Capital Hedosophia (IPOC) ending early next year.

Weekly Upgrades and Downgrades

During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fundamental health, I decided to revise my Portfolio Grader recommendations for 48 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly.

What Everyone Is Talking About

I awoke this morning to the same big news you did, that the President of the United States and the First Lady both tested positive for COVID-19. Both will be in quarantine in the White House for the foreseeable future. I certainly join others in hoping for a speedy recovery for them and all infected with the virus, and that efforts to find a successful vaccine pay off as fast as possible. As you can imagine, stock futures turned lower immediately when the news broke overnight, and the major U.S. indices opened down 1.2% to 2.0%. Hopes for another stimulus bill helped bring stocks off their lows pretty quickly. This news injects additional uncertainty in the market, and on today’s new episode of MoneyLine, I break down how this will affect stocks going forward. What does it mean heading into the election?

IBM Will Soon Become a Tech Leader

While IBM stock holders aren't necessarily bragging about their returns in 2020, the value proposition suggests that the best is yet to come.

ENLV Stock: Why Enlivex Is Soaring 70% Today

Enlivex just announced that it will launch Phase 2 trials for a plasma-based coronavirus treatment, and ENLV stock is soaring in response.

7 Investor Takeaways from the First Presidential Debate

How should investors react to the first presidential debate? Here are some of the biggest policy points for investors to keep in mind.

Another Brilliant Mind Joined Me for Today’s MoneyLine – You Don’t Want to Miss It

Get ready for some must-see TV! The first presidential debate is tonight, and it could get very interesting – for a lot of reasons. I suspect it may finally start to shed some light on who could win the election coming up quickly on November 3. The election is definitely a hot topic for investors right now, but it’s far from the only one. There’s the recent correction in the market… the continuing pandemic… upcoming earnings reports… and so much more at top of mind. That’s why on today’s new episode of MoneyLine, I welcome one of the brightest minds in the financial world – Ryan Detrick. Ryan is the chief market strategist at LPL Research, and he joins me for the entire show today.

AngioDynamics Earnings: ANGO Stock Soars 19% on Q1 Topper

AngioDynamics (ANGO) earnings for the company's fiscal first quarter of 2021 have ANGO stock on the rise Tuesday after beating estimates.

5 High-Yield MLPs Worth a Look This Fall

It may not be for several years energy stocks retrace their pre-pandemic price levels. But, with high-yields while you wait, and the opportunity for long-term upside, consider these five MLPs as we enter the fall.

Weekly Upgrades and Downgrades

During these busy times, it pays to stay on top of the latest profit opportunities. And today's blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company's fundamental health, I decided to revise my Portfolio Grader recommendations for 53 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly.

I Just Sat Down with Charlie Shrem AGAIN – You Want to Hear What We Talked About

Have you heard of Charlie Shrem? If you’ve been reading MoneyWire over the last week… you have. Charlie is a legend in the cryptocurrency world, and he’s my guest on the new episode of MoneyLine. He was likely one of the first to receive the white paper that started the crypto revolution, and as a result he’s been investing in bitcoin since it traded under $10. Now, he’s considered a pioneer and one of the most well-respected people in the industry. On today’s podcast, I have the pleasure of sitting down with Charlie. We talk about his 10 years in the industry, and he’ll tell you what he thinks about bitcoin and why he continues to buy it… regularly.

Still Reeling From Q2 Earnings Drop, Alteryx Stock Offers Opportunity

Data analytics company Alteryx was flying high until AYX stock fell off a cliff after Q2 earnings, offering a buying opportunity.

I’ve Uncovered a Stock That Has Everything We Look For…

It’s a big week for me. Yesterday I launched a brand-new cryptocurrency service with a bitcoin legend. And today is Tesla’s (TSLA) Battery Day. Longtime MoneyWire readers know that I’ve talked about the future of transportation and next-generation batteries for years. On today’s new episode of MoneyLine, I officially introduce my latest portfolio of altcoins. It’s part of Crypto Investor Network – a brand-new newsletter I created with Charlie Shrem. If you’ve never heard of Charlie, let me give you a very brief background: He is one of the original pioneers in the cryptocurrency industry… was buying bitcoin when it traded below $10… and founded one of the original bitcoin exchanges.